Estrella Immunopharma, Inc.
$1.81
0%
2026-04-21 06:42:00
www.estrellabio.com
NCM: ESLA
Explore Estrella Immunopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$80.21 M
Current Price
$1.81
52W High / Low
$3.15 / $0.78
Stock P/E
—
Book Value
$-0.27
Dividend Yield
—
ROCE
126.01%
ROE
428.83%
Face Value
—
EPS
$-0.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.58
Debt / Equity
—
Current Ratio
0.12
Quick Ratio
0.12
Forward P/E
-4.72
Price / Sales
—
Enterprise Value
$77.13 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NervGen Pharma Corp. | $4 | — | $464.51 M | — | -721.31% | -14.58% | $8.49 / $2.57 | $-0.03 |
| 2. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 3. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 4. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 5. | Generate Biomedicines, Inc. | $12.12 | — | $1.59 B | — | -94.79% | -81.72% | $15.32 / $11 | $-12.24 |
| 6. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 7. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -0.61 M | -4.8 M | -5.54 M | -2.1 M | -3.38 M |
| Net Profit | -0.61 M | -4.8 M | -5.54 M | -2.1 M | -3.38 M |
| EPS in Rs | -0.01 | -0.11 | -0.13 | -0.05 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.06 M | -7.31 M | -11.11 M | -1.69 M |
| Net Profit | -13.06 M | -7.31 M | -11.11 M | -1.69 M |
| EPS in Rs | -0.31 | -0.17 | -0.26 | -0.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.18 M | 4.45 M | 3.03 M | 4.92 M |
| Total Liabilities | 13.54 M | 0.18 M | 14.77 M | 5.96 M |
| Equity | -10.37 M | 4.27 M | -11.74 M | -1.04 M |
| Current Assets | 1.68 M | 4.45 M | 2.75 M | 4.92 M |
| Current Liabilities | 13.54 M | 0.18 M | 9.76 M | 0.95 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.79 M | -16.07 M | -1.34 M | -1.44 M |
| Investing CF | — | 4.96 M | -0.27 M | 0 M |
| Financing CF | 2.25 M | 12.79 M | 0 M | 5.53 M |
| Free CF | -1.79 M | -16.07 M | -1.34 M | -1.44 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 34.21% | -559.47% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.